The most common grade 3 or more adverse events were hypertension ( 33 [ 13 % ] of 245 patients receiving bevacizumab plus chemotherapy vs 17 [ 7 % ] of 238 patients receiving chemotherapy alone ) , neutropenia ( 29 [ 12 % ] vs 20 [ 8 % ] ) , and hand-foot syndrome ( 27 [ 11 % ] vs 25 [ 11 % ] ) .